KRTX Stock Recent News

Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.

Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.

Karuna has an experimental schizophrenia drug called KarXT up for U.S. government approval.

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. A final decision is expected in September 2024.

Karuna Therapeutics focuses on developing therapies that target muscarinic cholinergic receptors to treat psychosis and cognitive impairment in CNS disorders. The Company's lead asset, KarXT, has shown promising efficacy in phase III studies and has a unique mechanism of action compared to traditional antipsychotics. KarXT has potential applications in both schizophrenia and Alzheimer's disease psychosis, offering diversification to the investment thesis.

Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Alexis Smith - Head of Corporate Affairs and IR Bill Meury - President and CEO Jason Brown - CFO Andrew Miller - Founder and COO Will Kane - Chief Commercial Officer Conference Call Participants Yatin Suneja - Guggenheim Securities Myles Minter - William Blair Paul Matteis - Stifel Ash Verma - UBS Mohit Bansal - Wells Fargo David Amsellem - Piper Sandler Jay Olson - Oppenheimer Jeff Hung - Morgan Stanley Jason Butler - JMP Securities Operator Welcome to the Karuna Therapeutics Third Quarter 2023 Financial Results Conference Call. All participants are in a listen-only mode.

Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced it will be presenting new efficacy, safety, and tolerability analyses from its EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia at the upcoming Neuroscience Education Institute (NEI) Congress, to be held November 9-12, 202.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the following upcoming investor conferences: Guggenheim 5th Annual Inflammation & Immunology Conference Date: Tuesday, November 7, 2023 Time: 1:50 p.m. ET Stifel 2023 Healthcare Conference Date: Tuesday, November 14, 2023.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a live conference call and webcast on Thursday, November 2, 2023 at 8:00 a.m. ET to review third quarter 2023 financial results and provide a general business update. A live webcast of the presentation will be available on the Investor Rela.